On April 22, marijuana stocks spiked sharply on news that the Department of Justice was moving to reschedule regulated cannabis from Schedule I to Schedule III of the Controlled Substances Act. Tilray Brands, one of the sector's most closely watched public companies, jumped from roughly $7 to around $8 per share within hours - then gave back those gains and more, sliding toward $6. The sequence was telling. Not because markets overreacted, but because they eventually got it right.
What the Rescheduling Announcement Actually Said
The DOJ's Drug Enforcement Administration announcement did not, in fact, reschedule all marijuana products across the board. It granted immediate rescheduling only to FDA-approved and state-regulated medical marijuana products. Full rescheduling of cannabis from Schedule I to Schedule III - moving it out of the same statutory category as heroin and into the same tier as certain prescription drugs - remains subject to an administrative hearing process. Expedited, yes. Concluded, no.
That distinction matters enormously to operators and investors alike. Schedule III status, once fully in effect, would carry real financial consequences for cannabis businesses - most significantly, relief from Section 280E of the Internal Revenue Code. Under 280E, cannabis companies operating in federally illegal space are currently barred from deducting ordinary business expenses: payroll, rent, marketing, distribution costs. For a dispensary operator or a vertically integrated producer running on thin margins, the effective tax rate under 280E can be punishing in ways that have no parallel in other retail sectors. Rescheduling would remove that burden. That part of the argument is straightforward.
Here's the catch, though: even full rescheduling wouldn't solve the core structural problem for Canadian licensed producers like Tilray.
The Gap Between Rescheduling and Legalization
Tilray operates in a fundamentally different regulatory position than U.S. multi-state operators. As a Canada-based cannabis company, its ability to access the American market in any meaningful way depends not on rescheduling, but on federal legalization - or at minimum, a formal framework that allows cross-border trade or U.S. market entry. Schedule III status changes cannabis's federal classification. It does not open a legal domestic market to foreign-licensed cannabis producers.
To put it plainly: 280E relief helps U.S.-licensed operators who are already selling product. For Tilray and its Canadian peers, the more consequential federal action would be legislation that either opens the U.S. market to international operators or removes barriers to foreign investment in U.S. cannabis licensees. Rescheduling, valuable as it is on its own terms, doesn't get them there.
This is the market dynamic that likely drove the "buy the rumor, sell the news" pattern visible on April 22. Traders moved on the headline. Analysts looked at the fine print. The stock followed the analysts.
Company-Specific Pressures Compound the Regulatory Uncertainty
Regulatory tailwinds, even genuine ones, can't paper over company-specific fundamentals - and Tilray's are complicated. The company has faced persistent losses across reporting periods, and its cannabis-infused beverage line, a product category it moved into aggressively, has not delivered the performance investors were hoping for.
Cannabis beverages represent one of the more operationally demanding segments in regulated cannabis retail. SKU management is complex, shelf life creates inventory risk, distribution into licensed retail channels requires careful compliance coordination, and consumer adoption has been slower than early projections suggested. For dispensary operators carrying beverage SKUs, slow turns mean capital tied up in inventory that isn't moving - a pressure that compounds at scale.
Tilray's broader challenge reflects a sector-wide reality: cannabis companies built for a post-legalization world are operating in a pre-legalization one, carrying the overhead structures and growth ambitions of the former while subject to the regulatory constraints and tax treatment of the latter.
What This Means for Operators Watching the Federal Calendar
For dispensary owners, multi-state operators, wholesalers, and compliance professionals, the federal rescheduling process is worth watching carefully - but not as a near-term operational fix. The 280E issue is real and consequential. State-licensed adult-use and medical cannabis retailers currently absorb a tax burden that no comparable regulated retail business faces. If rescheduling proceeds through the administrative hearing process and takes full effect, it would meaningfully change the unit economics of licensed cannabis retail. That's not a small thing.
What it won't change: state-level licensing structures, excise tax obligations, seed-to-sale tracking requirements, packaging and labeling compliance, age-verification protocols, or the patchwork of local zoning rules that govern where dispensaries can operate. Those remain fully in force regardless of federal scheduling status. Operators who build their business plans around a rescheduling windfall without accounting for the persistent complexity of state-level compliance are reading the situation too optimistically.
The April 22 rally - and its swift reversal - is a useful frame for that broader point. Federal regulatory progress in cannabis tends to be incremental, contested, and slower than headlines suggest. The market, on this occasion, figured that out within the same trading session.
